Search research articles
Contact Us
Filters
Showing results (71-80 of 336) with videos related to
Page
of 34
Sort By:
Breast Cancer Research and Treatment
|
May 19, 2009
Editorial: Cost-effective analyses in Breast Cancer Research and Treatment [corrected]
Marc E Lippman, Stephen Ethier, Daniel F Hayes
Oncology (Williston Park, N.Y.)
|
February 4, 2010
CYP2D6 testing for breast cancer patients: is there more to the story?
N Lynn Henry, Daniel F Hayes, James M Rae
Journal of the National Cancer Institute
|
May 15, 2012
Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
Antonio C Wolff, M Elizabeth Hammond, Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2005
Gene expression profiling of breast cancer: a new tumor marker
Laura J van't Veer, Soonmyung Paik, Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2014
Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility
N Lynn Henry, Anne F Schott, Daniel F Hayes
Cancer Research
|
April 30, 2015
Genome Medicine in Cancer: What's in a Name?
Anne F Schott, Charles M Perou, Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2011
Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer
M Elizabeth Hammond, Daniel F Hayes, Antonio C Wolff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2022
Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective
Daniel L Hertz, Lisa M McShane, Daniel F Hayes
Archives of Pathology & Laboratory Medicine
|
August 26, 2014
Biomarkers and oncology: the path forward to a learning health system
Peter P Yu, Mark A Hoffman, Daniel F Hayes
Journal of the National Cancer Institute
|
May 1, 2008
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
Daniel F Hayes, Vered Stearns, James Rae, et al.
Page
of 34
Search research articles
Search
Showing results (71-80 of 336) with videos related to
Sort By:
Page
of 34
Breast Cancer Research and Treatment
|
May 19, 2009
Editorial: Cost-effective analyses in Breast Cancer Research and Treatment [corrected]
Marc E Lippman, Stephen Ethier, Daniel F Hayes
Oncology (Williston Park, N.Y.)
|
February 4, 2010
CYP2D6 testing for breast cancer patients: is there more to the story?
N Lynn Henry, Daniel F Hayes, James M Rae
Journal of the National Cancer Institute
|
May 15, 2012
Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
Antonio C Wolff, M Elizabeth Hammond, Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2005
Gene expression profiling of breast cancer: a new tumor marker
Laura J van't Veer, Soonmyung Paik, Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2014
Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility
N Lynn Henry, Anne F Schott, Daniel F Hayes
Cancer Research
|
April 30, 2015
Genome Medicine in Cancer: What's in a Name?
Anne F Schott, Charles M Perou, Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2011
Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer
M Elizabeth Hammond, Daniel F Hayes, Antonio C Wolff
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2022
Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective
Daniel L Hertz, Lisa M McShane, Daniel F Hayes
Archives of Pathology & Laboratory Medicine
|
August 26, 2014
Biomarkers and oncology: the path forward to a learning health system
Peter P Yu, Mark A Hoffman, Daniel F Hayes
Journal of the National Cancer Institute
|
May 1, 2008
A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
Daniel F Hayes, Vered Stearns, James Rae, et al.
Page
of 34